Jakafi Patient Meetings

FAQs

Quickly find answers to the most common questions about Jakafi Patient Meetings.

All Meetings

Q.

Who can attend, and what will be discussed?

A.

These meetings are for adults living with polycythemia vera (PV) and myelofibrosis (MF), as well as their friends and personal support team. Each meeting will review information about Jakafi® (ruxolitinib) as a possible treatment option. They are not designed for those living with Graft-Versus-Host Disease (GVHD).

The presenters at these meetings will not provide medical advice. Your healthcare professional is the best source of information about your condition.

Q.

Can I bring guests?

A.

Up to 4 friends, family members, or members of your personal support team are welcome to attend as well. Note that at this time, meetings hosted by Incyte are only available for U.S. residents.

Q.

How long is each meeting?

A.

Meetings hosted by Incyte are typically between 1.5 and 2 hours and can be attended either locally or online. The duration of each meeting depends on the number of questions asked by participants.

Q.

What is the difference between a local and an online meeting?

A.

Local meetings are held in person at a local hotel or meeting space. You will have the opportunity to meet and speak with other adults living with PV and MF and an Oncology Clinical Nurse Educator (OCNE).


Online meetings are offered for those who are unable to attend a local meeting. They are an easy way to experience a meeting from the comfort of your home. The same experienced OCNEs who present at the local meetings present the online meetings.

Q.

Will I receive a confirmation email and reminder after I register?

A.

Following registration, you will receive an email providing the time, place, directions, and in the case of online meetings, your meeting link. You can also refer to the meeting details page for the meeting you registered for or call us to confirm. Our phone number is (919) 256-2472. A reminder email is sent 2 days before the meeting. If you opt in during registration, you may also receive a phone call confirmation and a text confirming the date, time, and location of the meeting.

Q.

How much does it cost to attend?

A.

There is no cost to attend a meeting.

Q.

Who are the presenters? Are the online presenters the same as the local presenters?

A.

All presenters are Oncology Clinical Nurse Educators who are employed by Incyte Corporation. The same OCNEs who present at the local meetings will present at online meetings.

Local Meetings

Q.

Is there parking available? Is the venue handicap accessible?

A.

Parking is included for those attending the meeting. We work hard to ensure that our meeting space is easily accessible to all. If you need assistance, we can help make sure the venue can accommodate your needs.

Q.

Will there be food or a meal?

A.

Light hors d'oeuvres or a light lunch will be provided, depending on the time of the meeting.

Q.

Are overnight accommodations provided?

A.

We do not provide accommodations. However, you are welcome to book a hotel room on your own.

Online Meetings

Q.

How can I access the link to my online meeting?

A.

Your confirmation email will include a link to your online meeting. Two days before the meeting, you will receive the link again in a reminder email. You can use the link any time before the online meeting to add it to your calendar or see a brief summary of the meeting.

You can access the online meeting from any of your desktop, tablet, or mobile devices. To determine if your digital device can run the meeting, access the online venue (using the link provided in your confirmation email) from any of your desktop, tablet, or mobile devices. The meeting is compatible with most internet browsers, including Chrome, Firefox, Safari, Internet Explorer, and Edge. You can test your device by clicking the button below:
 

Test Your Device


Fifteen minutes before the online meeting is scheduled to begin, join by following the link in one of your emails. No plug-ins. No downloads.

Once you start the online meeting, you can

  • Watch the live presentation
  • Learn more about Jakafi as a possible treatment option
  • Ask the Oncology Clinical Nurse Educator questions through the integrated chat feature

For additional resources on PV and MF, visit Jakafi.com:

PV Resources MF Resources

The speaker will not provide medical advice. Your healthcare professional is the best source of information about your health.

Call us: (919) 256-2472

Email us:

Find a meeting

INDICATIONS AND USAGE

Jakafi is a prescription medicine used to treat adults with polycythemia vera who have already taken a medicine called hydroxyurea and it did not work well enough or they could not tolerate it.

Jakafi is also used to treat adults with certain types of myelofibrosis.

IMPORTANT SAFETY INFORMATION

Jakafi can cause serious side effects, including:

Low blood counts: Jakafi® (ruxolitinib) may cause low platelet, red blood cell, and white blood cell counts. If you develop bleeding, stop taking Jakafi and call your healthcare provider. Your healthcare provider will do a blood test to check your blood counts before you start Jakafi and regularly during your treatment. Your healthcare provider may change your dose of Jakafi or stop your treatment based on the results of your blood tests. Tell your healthcare provider right away if you develop or have worsening symptoms such as unusual bleeding, bruising, tiredness, shortness of breath, or a fever.

Infection: You may be at risk for developing a serious infection during treatment with Jakafi. Tell your healthcare provider if you develop any of the following symptoms of infection: chills, nausea, vomiting, aches, weakness, fever, painful skin rash or blisters.

Cancer: Some people have had certain types of non-melanoma skin cancers during treatment with Jakafi. Your healthcare provider will regularly check your skin during your treatment with Jakafi. Tell your healthcare provider if you develop any new or changing skin lesions during treatment with Jakafi.

Increases in cholesterol: You may have changes in your blood cholesterol levels during treatment with Jakafi. Your healthcare provider will do blood tests to check your cholesterol levels about every 8 to 12 weeks after you start taking Jakafi, and as needed.

Increased risk of major cardiovascular events such as heart attack, stroke or death in people who have cardiovascular risk factors and who are current or past smokers while using another JAK inhibitor to treat rheumatoid arthritis: Get emergency help right away if you have any symptoms of a heart attack or stroke while taking Jakafi, including: discomfort in the center of your chest that lasts for more than a few minutes, or that goes away and comes back, severe tightness, pain, pressure, or heaviness in your chest, throat, neck, or jaw, pain or discomfort in your arms, back, neck, jaw, or stomach, shortness of breath with or without chest discomfort, breaking out in a cold sweat, nausea or vomiting, feeling lightheaded, weakness in one part or on one side of your body, slurred speech

Increased risk of blood clots: Blood clots in the veins of your legs (deep vein thrombosis, DVT) or lungs (pulmonary embolism, PE) have happened in people taking another JAK inhibitor for rheumatoid arthritis and may be life-threatening. Tell your healthcare provider right away if you have any signs and symptoms of blood clots during treatment with Jakafi, including: swelling, pain, or tenderness in one or both legs, sudden, unexplained chest or upper back pain, shortness of breath or difficulty breathing

Possible increased risk of new (secondary) cancers: People who take another JAK inhibitor for rheumatoid arthritis have an increased risk of new (secondary) cancers, including lymphoma and other cancers. People who smoke or who smoked in the past have an added risk of new cancers.

The most common side effects of Jakafi include: for certain types of myelofibrosis (MF) and polycythemia vera (PV) — low platelet or red blood cell counts, bruising, dizziness, headache, and diarrhea; for acute GVHD — low platelet counts, low red or white blood cell counts, infections, and swelling; and for chronic GVHD — low red blood cell or platelet counts and infections including viral infections.

These are not all the possible side effects of Jakafi. Ask your pharmacist or healthcare provider for more information. Call your doctor for medical advice about side effects.

Before taking Jakafi, tell your healthcare provider about: all the medications, vitamins, and herbal supplements you are taking and all your medical conditions, including if you have an infection, have or had low white or red blood cell counts, have or had tuberculosis (TB) or have been in close contact with someone who has TB, had shingles (herpes zoster), have or had hepatitis B, have or had liver or kidney problems, are on dialysis, have high cholesterol or triglycerides, had cancer, are a current or past smoker, had a blood clot, heart attack, other heart problems or stroke, or have any other medical condition. Take Jakafi exactly as your healthcare provider tells you. Do not change your dose or stop taking Jakafi without first talking to your healthcare provider.

Women should not take Jakafi while pregnant or planning to become pregnant. Do not breastfeed during treatment with Jakafi and for 2 weeks after the final dose.

Please see the Full Prescribing Information, which includes a more complete discussion of the risks associated with Jakafi.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

You may also report side effects to Incyte Medical Information at 1-855-463-3463.